Castle Biosciences
New York State DOH Approves Castle Biosciences' Barrett’s Esophagus Test
The TissueCypher assay is designed to identify patients with Barrett's esophagus who are at risk of progressing to esophageal cancer.
Using real-world data from NCI's SEER registry, researchers found that patients who got Castle's DecisionDx-Melanoma test had better survival outcomes than untested patients.
The company discussed what it believes are compelling new results on the impact of its testing on patient outcomes during a call discussing its Q1 earnings.
Castle Biosciences, VHA Expand Supply Contract to Cover Full Skin Cancer Test Portfolio
The new contract with the Veterans Health Administration makes all five of the company's skin cancer assays available for veterans, active-duty military, and family members.
In Brief This Week: Taiho Oncology, PamGene, Mursla, Autolus Therapeutics, Clovis Oncology
News items for the week of March 28, 2022.